Exploring the role of metformin in anticancer treatments: A systematic review

Drugs of Today

Volumn 50, Issue 9, 2014, Pages 623-640

  Miranda, V C ^a   Barroso Sousa, R ^a   Glasberg, J ^a   Riechelmann, R P ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cancer; Diabetes; Metformin

Indexed keywords

METFORMIN; ANTIDIABETIC AGENT;

ANTIPROLIFERATIVE ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; COLORECTAL CANCER; DRUG MECHANISM; GYNECOLOGIC CANCER; HUMAN; LIVER CANCER; LUNG CANCER; META ANALYSIS; NONHUMAN; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; REVIEW; SYSTEMATIC REVIEW; NEOPLASM;

HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; NEOPLASMS;

EID: 84907701160     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2014.50.9.2229920     Document Type: Review

References (100)

1. Cusi, K., Consoli, A., DeFronzo, R.A. Metabolic effects of metformin on glucose and lactate metabolism in noninsulindependent diabetes mellitus. J Clin endocrinol Metab 1996, 81(11): 4059-67.
2. Belfiore, A., Frasca, F. IGF and insulin receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 2008, 13(4): 381-406.
3. Frasca, F., Pandini, G., Sciacca, L., Pezzino, V., Squatrito, S., Belfiore, A., Vigneri, R. The role of insulin receptors and IGFI receptors in cancer and other diseases. Arch Physiol Biochem 2008, 114(1): 23-37.
4. Mulligan, A.M., O'Malley, F.P., ennis, M., Fantus, I.G., Goodwin, P.J. Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Breast Cancer res Treat 2007, 106(1): 39-47.
5. Decensi, A., Puntoni, M., Goodwin, P., Cazzaniga, M., Gennari, A., Bonanni, B., Gandini, S. Metformin and cancer risk in diabetic patients: A systematic review and meta-analysis. Cancer Prev Res (Phila) 2010, 3(11): 1451-61.
6. Ish-Shalom, D., Christoffersen, C.T., Vorwerk, P., Sacerdoti- Sierra, N., Shymko, R.M., Naor, D., De Meyts, P. Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor. Diabetologia 1997, 40 Suppl 2: S25-S31.
7. Basen-Engquist, K., Chang, M. Obesity and cancer risk: recent review and evidence. Curr Oncol Rep 2011, 13(1): 71-6.
8. Goodwin, P.J., Ennis, M., Pritchard, K.I. et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 2002, 20(1): 42-51.
9. Dowling, R.J., Zakikhani, M., Fantus, I.G., Pollak, M., Sonenberg, N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer res 2007, 67(22): 10804-12.
10. Inoki, K., Zhu, T., Guan, K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003, 115(5): 577-90.
11. Zakikhani, M., Dowling, R., Fantus, I.G., Sonenberg, N., Pollak, M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006, 66(21): 10269-73.
12. Kalender, A., Selvaraj, A., Kim, S.Y. et al. Met form in, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 2010, 11(5): 390-401.
13. Foretz, M., Hebrard, S., Leclerc, J. et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin invest 2010, 120(7): 2355-69.
14. Engelman, J.A., Cantley, L.C. Chemoprevention meets glucose control. Cancer Prev res (Phila) 2010, 3(9): 1049-52.
15. Memmott, R.M., Dennis, P.A. LKB1 and mammalian target of rapamycin as predictive factors for the anticancer efficacy of metformin. J Clin Oncol 2009, 27(34): e226; author reply e7.
16. Higurashi, T., Takahashi, H., Endo, H. et al. Metformin efficacy and safety for colorectal polyps: A double-blind randomized controlled trial. BMC Cancer 2012, 12: 118.
17. Lee, J.H., Jeon, S.M., Hong, S.P., Cheon, J.H., Kim, T.I., Kim, W.H. Metformin use is associated with a decreased incidence of colorectal adenomas in diabetic patients with previous colorectal cancer. Dig Liver Dis 2012, 44(12): 1042-7.
18. Tomimoto, A., endo, H., Sugiyama, M. et al. Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci 2008, 99(11): 2136-41.
19. Hosono, K., Endo, H., Takahashi, H. et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila) 2010, 3(9): 1077-83.
20. Lee, J.H., Kim, T.I., Jeon, S.M., Hong, S.P., Cheon, J.H., Kim, W.H. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int J Cancer 2012, 131(3): 752-9.
21. Tseng, C.H. Diabetes, metformin use, and colon cancer: A population-based cohort study in Taiwan. Eur J endocrinol 2012, 167(3): 409-16.
22. Zhang, Z.J., Zheng, Z.J., Kan, H., Song, Y., Cui, W., Zhao, G., Kip, K.E. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: A meta-analysis. Diabetes Care 2011, 34(10): 2323-8.
23. Miranda, V.C., Dib-Faria, L., Braghiroli, M.I. A phase II trial of metformin and fluorouracil (MetFU) for patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard treatment. J Clin Oncol 2014, 32(Suppl. 3): Abst 601.
24. Cossor, F.I., Adams-Campbell, L.L., Chlebowski, R.T. et al. Diabetes, metformin use, and colorectal cancer survival in postmenopausal women. Cancer epidemiol 2013, 37(5): 742-9.
25. Bodmer, M., Becker, C., Meier, C., Jick, S.S., Meier, C.R. Use of metformin is not associated with a decreased risk of colorectal cancer: A case-control analysis. Cancer epidemiol Biomarkers Prev 2012, 21(2): 280-6.
26. Garrett, C.R., Hassabo, H.M., Bhadkamkar, N.A. et al. Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. Br J Cancer 2012, 106(8): 1374-8.
27. Spillane, S., Bennett, K., Sharp, L., Barron, T.I. A cohort study of metformin exposure and survival in patients with stage I-III colorectal cancer. Cancer epidemiol Biomarkers Prev 2013, 22(8): 1364-73.
28. Kanadiya, M.K., Gohel, T.D., Sanaka, M.R., Thota, P.N., Shubrook, J.H. Jr. Relationship between type-2 diabetes and use of metformin with risk of colorectal adenoma in an American population receiving colonoscopy. J Diabetes Complications 2013, 27(5): 463-6.
29. Kisfalvi, K., Eibl, G., Sinnett-Smith, J., Rozengurt, E. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 2009, 69(16): 6539-45.
30. Nair, V., Pathi, S., Jutooru, I. et al. Metformin inhibits pancreatic cancer cell and tumor growth and downregulates Sp transcription factors. Carcinogenesis 2013, 34(12): 2870-9.
31. Karnevi, E., Said, K., Andersson, R., Rosendahl, A.H. Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells. BMC Cancer 2013, 13: 235.
32. Singh, S., Singh, P.P., Singh, A.G., Murad, M.H., Mcwilliams, R.R., Chari, S.T. Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: A systematic review and meta-analysis. Am J Gastroenterol 2013, 108(4): 510-9.
33. Hwang, A.L., Haynes, K., Hwang, W.T., Yang, Y.X. Metformin and survival in pancreatic cancer: A retrospective cohort study. Pancreas 2013, 42(7): 1054-9.
34. Sadeghi, N., Abbruzzese, J.L., Yeung, S.C., Hassan, M., Li, D. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res 2012, 18(10): 2905-12.
35. Treatment of patients with advanced pancreatic cancer after gemcitabine failure (NCT01971034). ClinicalTrials.gov web site, Accessed September 22, 2014.
36. Nkontchou, G., Cosson, E., Aout, M. et al. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin endocrinol Metab 2011, 96(8): 2601-8.
37. Zhang, Z.J., Zheng, Z.J., Shi, r., Su, Q., Jiang, Q., Kip, K.E. Metformin for liver cancer prevention in patients with type 2 diabetes: A systematic review and meta-analysis. J Clin Endocrinol Metab 2012, 97(7): 2347-53.
38. Zhang, H., Gao, C., Fang, L., Zhao, H.C., Yao, S.K. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: A meta-analysis. Scand J Gastroenterol 2013, 48(1): 78-87.
39. Singh, S., Singh, P.P., Singh, A.G., Murad, M.H., Sanchez, W. Anti-diabetic medications and the risk of hepatocellular cancer: A systematic review and meta-analysis. Am J Gastroenterol 2013, 108(6): 881-91.
40. Lee, M.S., Hsu, C.C., Wahlqvist, M.L., Tsai, H.N., Chang, Y.H., Huang, Y.C. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: A representative population prospective cohort study of 800, 000 individuals. BMC Cancer 2011, 11: 20.
41. Chen, H.P., Shieh, J.J., Chang, C.C. et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 2013, 62(4): 606-15.
42. Hassan, M.M., Curley, S.A., Li, D. et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 2010, 116(8): 1938-46.
43. Lai, S.W., Chen, P.C., Liao, K.F., Muo, C.H., Lin, C.C., Sung, F.C. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: A population- based cohort study. Am J Gastroenterol 2012, 107(1): 46-52.
44. Donadon, V., Balbi, M., Mas, M.D., Casarin, P., Zanette, G. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 2010, 30(5): 750-8.
45. Siegel, R., Ma, J., Zou, Z., Jemal, A. Cancer statistics, 2014. CA Cancer J Clin 2014, 64(1): 9-29.
46. Ma, J., Li, H., Giovannucci, E. et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancerspecific mortality in men with prostate cancer: A long-term survival analysis. Lancet Oncol 2008, 9(11): 1039-47.
47. Flanagan, J., Gray, P.K., Hahn, N., Hayes, J., Myers, L.J., Carney-Doebbeling, C., Sweeney, C.J. Presence of the metabolic syndrome is associated with shorter time to castrationresistant prostate cancer. Ann Oncol 2011, 22(4): 801-7.
48. D'Amico, A.V., Braccioforte, M.H., Moran, B.J., Chen, M.H. Causes of death in men with prevalent diabetes and newly diagnosed high- versus favorable-risk prostate cancer. Int J radiat Oncol Biol Phys 2010, 77(5): 1329-37.
49. Laaksonen, D.E., Niskanen, L., Punnonen, K. et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004, 27(5): 1036-41.
50. Ben Sahra, I., Laurent, K., Loubat, A. et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008, 27(25): 3576-86.
51. Murtola, T.J., Tammela, T.L., Lahtela, J., Auvinen, A. Antidiabetic medication and prostate cancer risk: A population- based case-control study. Am J epidemiol 2008, 168(8): 925-31.
52. Wright, J.L., Stanford, J.L. Metformin use and prostate cancer in Caucasian men: results from a population-based casecontrol study. Cancer Causes Control 2009, 20(9): 1617-22.
53. Azoulay, L., Dell'Aniello, S., Gagnon, B., Pollak, M., Suissa, S. Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer epidemiol Biomarkers Prev 2011, 20(2): 337-44.
54. Margel, D., Urbach, D., Lipscombe, L.L., Bell, C.M., Kulkarni, G., Austin, P.C., Fleshner, N. Association between metformin use and risk of prostate cancer and its grade. J Natl Cancer Inst 2013, 105(15): 1123-31.
55. Patel, T., Hruby, G., Badani, K., Abate-Shen, C., McKiernan, J.M. Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin. Urology 2010, 76(5): 1240-4.
56. Rieken, M., Kluth, L.A., Xylinas, E. et al. Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer. world J Urol 2014, 32(4): 999-1005.
57. Kaushik, D., Karnes, R.J., Eisenberg, M.S., rangel, L.J., Carlson, R.E., Bergstralh, E.J. Effect of metformin on prostate cancer outcomes after radical prostatectomy. Urol Oncol 2014, 32(1): 43 e1-7.
58. He, X.X., Tu, S.M., Lee, M.H., Yeung, S.C. Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol 2011, 22(12): 2640-5.
59. Spratt, D.E., Zhang, C., Zumsteg, Z.S., Pei, X., Zhang, Z., Zelefsky, M.J. Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 2013, 63(4): 709-16.
60. Margel, D., Urbach, D.R., Lipscombe, L.L., Bell, C.M., Kulkarni, G., Austin, P.C., Fleshner, N. Metformin use and allcause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol 2013, 31(25): 3069-75.
61. Rothermundt, C., Hayoz, S., Templeton, A.J. et al. Metformin in chemotherapy-naive castration-resistant prostate cancer: A multicenter phase 2 trial (SAKK 08/09). Eur Urol 2014, Advanced publication.
62. Allott, E.H., Abern, M.R., Gerber, L. et al. Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. Prostate Cancer Prostatic Dis 2013, 16(4): 391-7.
63. Duggan, C., irwin, M.L., Xiao, L. et al. Associations of insulin resistance and adiponectin with mortality in women with breast cancer. J Clin Oncol 2011, 29(1): 32-9.
64. Irwin, M.L., Duggan, C., wang, C.Y. et al. Fasting C-peptide levels and death resulting from all causes and breast cancer: The health, eating, activity, and lifestyle study. J Clin Oncol 2011, 29(1): 47-53.
65. Lipscombe, L.L., Goodwin, P.J., Zinman, B., McLaughlin, J.R., Hux, J.E. The impact of diabetes on survival following breast cancer. Breast Cancer Res Treat 2008, 109(2): 389-95.
66. Erickson, K., Patterson, R.E., Flatt, S.W. et al. Clinically defined type 2 diabetes mellitus and prognosis in early-stage breast cancer. J Clin Oncol 2011, 29(1): 54-60.
67. Jiralerspong, S., Kim, E.S., Dong, W., Feng, L., Hortobagyi, G.N., Giordano, S.H. Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients. Ann Oncol 2013, 24(10): 2506-14.
68. Alimova, I.N., Liu, B., Fan, Z., Edgerton, S.M., Dillon, T., Lind, S.E., Thor, A.D. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009, 8(6): 909-15.
69. Libby, G., Donnelly, L.A., Donnan, P.T., Alessi, D.R., Morris, A.D., Evans, J.M. New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes. Diabetes Care 2009, 32(9): 1620-5.
70. Currie, C.J., Poole, C.D., Gale, E.A. The influence of glucoselowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009, 52(9): 1766-77.
71. Chlebowski, R.T., McTiernan, A., Wactawski-Wende, J. et al. Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol 2012, 30(23): 2844-52.
72. Van Staa, T.P., Patel, D., Gallagher, A.M., De Bruin, M.L. Glucose-lowering agents and the patterns of risk for cancer: A study with the General Practice Research Database and secondary care data. Diabetologia 2012, 55(3): 654-65.
73. Bodmer, M., Meier, C., Krahenbuhl, S., Jick, S.S., Meier, C.R. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010, 33(6): 1304-8.
74. Bosco, J.L., Antonsen, S., Sorensen, H.T., Pedersen, L., Lash, T.L. Metformin and incident breast cancer among diabetic women: A population-based case-control study in Denmark. Cancer epidemiol Biomarkers Prev 2011, 20(1): 101-11.
75. Ruiter, R., Visser, L.E., Van Herk-Sukel, M.P. et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large populationbased follow-up study. Diabetes Care 2012, 35(1): 119-24.
76. Col, N.F., Ochs, L., Springmann, V., Aragaki, A.K., Chlebowski, R.T. Metformin and breast cancer risk: A metaanalysis and critical literature review. Breast Cancer Res Treat 2012, 135(3): 639-46.
77. Jiralerspong, S., Palla, S.L., Giordano, S.H. et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009, 27(20): 3297-302.
78. Bonanni, B., Puntoni, M., Cazzaniga, M. et al. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol 2012, 30(21): 2593-600.
79. Hadad, S., Iwamoto, T., Jordan, L. et al. Evidence for biological effects of metformin in operable breast cancer: A preoperative, window-of-opportunity, randomized trial. Breast Cancer res Treat 2011, 128(3): 783-94.
80. Niraula, S., Dowling, R.J., ennis, M. et al. Metformin in early breast cancer: A prospective window of opportunity neoadjuvant study. Breast Cancer res Treat 2012, 135(3): 821-30.
81. Bayraktar, S., Hernadez-Aya, L.F., Lei, X. et al. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 2012, 118(5): 1202-11.
82. He, X., Esteva, F.J., Ensor, J., Hortobagyi, G.N., Lee, M.H., Yeung, S.C. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann Oncol 2012, 23(7): 1771-80.
83. Lega, I.C., Austin, P.C., Gruneir, A., Goodwin, P.J., Rochon, P.A., Lipscombe, L.L. Association between metformin therapy and mortality after breast cancer: A population-based study. Diabetes Care 2013, 36(10): 3018-26.
84. Gunter, M.J., Hoover, D.R., Yu, H. et al. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer epidemiol Biomarkers Prev 2008, 17(4): 921-9.
85. Mu, N., Zhu, Y., wang, Y., Zhang, H., Xue, F. Insulin resistance: A significant risk factor of endometrial cancer. Gynecol Oncol 2012, 125(3): 751-7.
86. Becker, C., Jick, S.S., Meier, C.r., Bodmer, M. Metformin and the risk of endometrial cancer: A case-control analysis. Gynecol Oncol 2013, 129(3): 565-9.
87. Ko, E.M., walter, P., Jackson, A. et al. Metformin is associated with improved survival in endometrial cancer. Gynecol Oncol 2014, 132(2): 438-42.
88. Bodmer, M., Becker, C., Meier, C., Jick, S.S., Meier, C.R. Use of metformin and the risk of ovarian cancer: A case-control analysis. Gynecol Oncol 2011, 123(2): 200-4.
89. Romero, I.L., McCormick, A., Mcewen, K.A. et al. Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol 2012, 119(1): 61-7.
90. Kumar, S., Meuter, A., Thapa, P. et al. Metformin intake is associated with better survival in ovarian cancer: A case-control study. Cancer 2013, 119(3): 555-62.
91. Nevadunsky, N.S., Van Arsdale, A., Strickler, H.D. et al. Metformin use and endometrial cancer survival. Gynecol Oncol 2014, 132(1): 236-40.
92. Roett, M.A., Evans, P. Ovarian cancer: An overview. Am Fam Physician 2009, 80(6): 609-16.
93. Husseinzadeh, N., Husseinzadeh, H.D. mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: A critical review. Gynecol Oncol 2014, 133(2): 375- 81.
94. Metformin hydrochloride, carboplatin, and paclitaxel in treating patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer (NCT02050009). ClinicalTrials.gov web site, Accessed September 22, 2014.
95. Paclitaxel and carboplatin with or without metformin hydrochloride in treating patients with stage III, IV, or recurrent endometrial cancer (NCT02065687). ClinicalTrials.gov web site, Accessed September 22, 2014.
96. Tan, B.X., Yao, W.X., Ge, J. et al. Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes. Cancer 2011, 117(22): 5103-11.
97. Bodmer, M., Becker, C., Jick, S.S., Meier, C.R. Metformin does not alter the risk of lung cancer: A case-control analysis. Lung Cancer 2012, 78(2): 133-7.
98. Smiechowski, B.B., Azoulay, L., Yin, H., Pollak, M.N., Suissa, S. The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. Diabetes Care 2013, 36(1): 124- 9.
99. Mazzone, P.J., Rai, H., Beukemann, M., Xu, M., Jain, A., Sasidhar, M. The effect of metformin and thiazolidinedione use on lung cancer in diabetics. BMC Cancer 2012, 12: 410.
100. Lai, S.W., Liao, K.F., Chen, P.C., Tsai, P.Y., Hsieh, D.P., Chen, C.C. Antidiabetes drugs correlate with decreased risk of lung cancer: A population-based observation in Taiwan. Clin Lung Cancer 2012, 13(2): 143-8.